Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00237-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsmi=288624173&_hsenc=p2ANqtz-8R8BW_kUjHpN69ZDvUBF_i9b-BqJhp9bRBbuKk2ti8scPJZUb1IVrUgG0YGK2LeNe0F5CoFDtFCupjciWEv2aQ64Lx5Q&utm_content=288125594&utm_source=hs_email